These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17684971)

  • 21. [Results of the multicenter prospective study of cerebrolysin safety and efficacy in acute stroke].
    Skwortsova VI; Stakhovskaia LV; Shamalov NA; Kerbikov OB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Suppl 16():41-5. PubMed ID: 18196634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening of mild cognitive impairment in Chinese older adults--a multistage validation of the Chinese abbreviated mild cognitive impairment test.
    Lam LC; Tam CW; Lui VW; Chan WC; Chan SS; Chiu HF; Leung T; Tham MK; Ho KS; Chan WM
    Neuroepidemiology; 2008; 30(1):6-12. PubMed ID: 18204291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Monitoring of neurotrophic factors and cognitive function in patients with traumatic brain injury].
    Karakulova YV; Selyanina NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):34-37. PubMed ID: 29171486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].
    Skvortsova VI; Stakhovskaia LV; Gubskiĭ LV; Shamalov NA; Tikhonova IV; Smychkov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; (Suppl 11):51-5. PubMed ID: 15559222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Asthenic disorders and cognitive dysfunction in patients with tension headache].
    Chutko LS; Surushkina SIu; Rozhkova AV; Iakovenko EA; Bykova IuL; Nikishina IS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(5):31-5. PubMed ID: 23739500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].
    Roshchina IF; Gavrilova SI; Zharikov GA; Kalyn IaB; Kolykhalov IV; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(1):52-5. PubMed ID: 15704485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.
    Alvarez XA; Lombardi VR; Corzo L; Pérez P; Pichel V; Laredo M; Hernández A; Freixeiro F; Sampedro C; Lorenzo R; Alcaraz M; Windisch M; Cacabelos R
    J Neural Transm Suppl; 2000; 59():315-28. PubMed ID: 10961443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).
    Damulin IV; Koberskaya NN; Mkhitaryan EA
    Neurosci Behav Physiol; 2008 Jul; 38(6):639-45. PubMed ID: 18607744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy].
    Kontsevoĭ VA; Medvedev AV; Andrusenko MP; Zvenigorodskaia IuV; Sheshenin VS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(6):39-44. PubMed ID: 11517474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke].
    Shamalov NA; Stakhovskaia LV; Burenchev DV; Kichuk IV; Tvorogova TV; Botsina AIu; Smychkov AS; Kerbikov OB; Moessler H; Novak P; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):34-7. PubMed ID: 21626816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
    Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N;
    Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of prolonged therapy of vascular dementia].
    Klin Med (Mosk); 2011; 89(5):57-60. PubMed ID: 22242270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Perstenev SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):37-42. PubMed ID: 19008850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.